tetano
Editor, Senior Moderator
Heart Views
. 2024 Oct-Dec;25(4):197-211.
doi: 10.4103/heartviews.heartviews_62_24. Epub 2025 May 10. A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination
Mohammed Thamer Ali[SUP] 1 [/SUP], Ammar Chapra[SUP] 1 [/SUP], Samah F A Mohamed[SUP] 2 3 [/SUP], Abdel Naser Ghareeb[SUP] 2 4 [/SUP], Maryam Al Kuwari[SUP] 2 [/SUP], Sabir Abdul Karim[SUP] 5 [/SUP], Tahir Hamid[SUP] 1 [/SUP], Emad Ahmed Ali Hassan[SUP] 1 [/SUP], Awad Al Qahtani[SUP] 1 [/SUP], Nidal Asaad[SUP] 1 [/SUP], Jassim Al Suwaidi[SUP] 1 [/SUP]
Affiliations
Background: COVID-19 messenger RNA (mRNA) vaccine-related myocarditis, though rare, primarily affects young males and often presents its symptoms within the 1st week postvaccination.
Aims and objectives: To assess the long-term outcomes of individuals diagnosed with myocarditis following COVID-19 vaccination.
Materials and methods: We conducted a case series analysis involving 17 patients diagnosed with inflammatory myocarditis.
Results: Symptoms in these patients typically appeared 24-96 h after receiving the COVID-19 mRNA vaccine. Fortunately, the prognosis for these patients is generally favorable, characterized by good short-term recovery and minimal long-term consequences. Follow-up cardiac magnetic resonance imaging (CMR) among our patients revealed alongside a preserved ejection fraction, the absence of fibrosis in 7 out of 13 (54%) patients with minimal residual fibrosis in 5 (38%) patients, whereas the remaining one patient demonstrated fibrosis consistent with hypertrophic cardiomyopathy.
Conclusion: Despite the seemingly benign nature of COVID-19 mRNA vaccine-related myocarditis thus far, it is crucial to emphasize the necessity of prolonged clinical and CMR follow-up exceeding 1 year. Extended monitoring is essential to gain a deeper understanding of the true nature of this condition and its potential implications. This comprehensive approach will contribute significantly to ensuring the ongoing safety and efficacy of COVID-19 vaccination programs.
Keywords: COVID-19 vaccine; myocarditis; severe acute respiratory syndrome coronavirus 2.
. 2024 Oct-Dec;25(4):197-211.
doi: 10.4103/heartviews.heartviews_62_24. Epub 2025 May 10. A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination
Mohammed Thamer Ali[SUP] 1 [/SUP], Ammar Chapra[SUP] 1 [/SUP], Samah F A Mohamed[SUP] 2 3 [/SUP], Abdel Naser Ghareeb[SUP] 2 4 [/SUP], Maryam Al Kuwari[SUP] 2 [/SUP], Sabir Abdul Karim[SUP] 5 [/SUP], Tahir Hamid[SUP] 1 [/SUP], Emad Ahmed Ali Hassan[SUP] 1 [/SUP], Awad Al Qahtani[SUP] 1 [/SUP], Nidal Asaad[SUP] 1 [/SUP], Jassim Al Suwaidi[SUP] 1 [/SUP]
Affiliations
- PMID: 40488147
- PMCID: PMC12139649
- DOI: 10.4103/heartviews.heartviews_62_24
Background: COVID-19 messenger RNA (mRNA) vaccine-related myocarditis, though rare, primarily affects young males and often presents its symptoms within the 1st week postvaccination.
Aims and objectives: To assess the long-term outcomes of individuals diagnosed with myocarditis following COVID-19 vaccination.
Materials and methods: We conducted a case series analysis involving 17 patients diagnosed with inflammatory myocarditis.
Results: Symptoms in these patients typically appeared 24-96 h after receiving the COVID-19 mRNA vaccine. Fortunately, the prognosis for these patients is generally favorable, characterized by good short-term recovery and minimal long-term consequences. Follow-up cardiac magnetic resonance imaging (CMR) among our patients revealed alongside a preserved ejection fraction, the absence of fibrosis in 7 out of 13 (54%) patients with minimal residual fibrosis in 5 (38%) patients, whereas the remaining one patient demonstrated fibrosis consistent with hypertrophic cardiomyopathy.
Conclusion: Despite the seemingly benign nature of COVID-19 mRNA vaccine-related myocarditis thus far, it is crucial to emphasize the necessity of prolonged clinical and CMR follow-up exceeding 1 year. Extended monitoring is essential to gain a deeper understanding of the true nature of this condition and its potential implications. This comprehensive approach will contribute significantly to ensuring the ongoing safety and efficacy of COVID-19 vaccination programs.
Keywords: COVID-19 vaccine; myocarditis; severe acute respiratory syndrome coronavirus 2.